-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Program: Oral and Poster Abstracts
Type: Poster
Monday, December 12, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)

Cathelijne Fokkema, MD1*, Madelon M.E. de Jong, MD1*, Sabrin Tahri, MD1*, Davine Hofste Op Bruinink, MD1*, Zoltan Kellermayer, MD, PhD1*, Chelsea den Hollander, BSc1*, Michael Vermeulen, BSc1*, Natalie Papazian, BSc1*, Mark van Duin, PhD1*, Remco Hoogenboezem, MSc1*, Michiel J.W. Wevers, MSc1*, Vincent H.J. van der Velden, PhD2*, Mathijs A. Sanders, PhD, MSc1*, Annemiek Broijl, MD, PhD3*, Pieter Sonneveld, MD1 and Tom Cupedo, PhD1*

1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
2Department of Immunology, Erasmus University Medical Center, Rotterdam, Netherlands
3Erasmus MC Cancer Institute, Rotterdam, Netherlands

Mohammad Issam Abu Zaid, MBBS1, Parvathi Sudha, MS2*, Travis S Johnson, PhD3, Vivek S. Chopra, PhD4*, Cedric E. Dos Santos, PhD5, Michael Nixon, MSN, MPH4*, Attaya Suvannasankha, MD6*, Sherif S Farag, MD, PhD7, Kelvin P. Lee, MD8, Rafat Abonour, MD2 and Brian A. Walker, PhD2

1Melvin and Bren Simon Comprehensive Cancer Center, Indiana Cancer Pavilion, Indianapolis, IN
2Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University, Indianapolis, IN
3Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN
4Genentech, Inc., South San Francisco, CA
5Genentech, Inc., San Francisco, CA
6Indiana University Simon Cancer Center, Indiana University and Roudebush VAMC, Indianapolis, IN
7Division of Hematology and Oncology, Department of Medicine, Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN
8Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN

Zainul Hasanali, MD, PhD1, Alfred L. Garfall2,3,4,5,6*, Martin P. Carroll, MD7, Anthony Secreto1*, Nicolas Skuli, PhD8*, Carly Roman1,9*, Leonard Shultz, PhD10*, Neil Sheppard, D.Phil11*, Edward A. Stadtmauer, MD2,12 and David Allman, PhD13*

1University of Pennsylvania, Philadelphia, PA
2Abramson Cancer Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
3Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA
4Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
5Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
6Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
7Division of Hematology/Oncology, Department of Medicine, The Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA
8University of Pennsylvania, Phiadelphia, PA
9Emory University, Atlanta, GA
10The Jackson Laboratory, Bar Harbor, ME
11University of Pennsyvlania, Philadelphia, PA
12Division of Hematology and Oncology, Abramson Cancer Center University of Pennsylvania, Philadelphia, PA
13Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

Sigrún Thorsteinsdóttir, MD, PhD1,2, Jon Þórir Oskarsson, MSc3*, Sæmundur Rögnvaldsson, MD4,5*, Gauti Gíslason1*, Thor Aspelund, PhD1*, Gudrún Ásta Sigurdardóttir1*, Ásdis Rósa Thórdardottir1*, Brynjar Vidarsson, MD5, Páll Torfi Onundarson, MD5, Bjarni Agnar Agnarsson, MD5*, Margrét Sigurdardóttir, MD5*, Ingunn Thorsteinsdóttir, MD, PhD5*, Ísleifur Ólafsson, MD, PhD5*, Elias Eythorsson, MD, PhD5*, Ásbjorn Jónsson, MD6*, Malin Hultcrantz, MD, PhD7, Ola Landgren, MD8, Stephen Harding, PhD9, Brian G.M. Durie, MD10, Thorvardur Jon Love, MD, PhD1* and Sigurdur Y Kristinsson, MD, PhD1,5

1Faculty of Medicine, University of Iceland, Reykjavik, Iceland
2Department of Hematology, Rigshospitalet, Copenhagen, Copenhagen, Denmark
3Faculty of Medicine, University of Iceland, Reykjavik, Reykjavik, Iceland
4Faculty of Medicine, University of Iceland, Reykjavík, Iceland
5Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland
6Akureyri Hospital, Akureyri, Iceland
7Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
8Myeloma Division, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
9The Binding Site Inc., Birmingham, United Kingdom
10Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA

Johannes M. Waldschmidt, MD1,2, Sankalp Arora, MD3*, Tushara Vijaykumar1*, Noori Sotudeh, PhD4*, Praveen Anand, PhD1*, Hannah Stuart1*, Julia Frede, PhD, MPhil1, Tim Campbell5*, Shari M. Kaiser, PhD5*, Manisha Lamba, PhD5*, Nikhil C Munshi, MD, PhD6, Kenneth C. Anderson, MD1, Andrew J. Yee, MD, PhD7, Birgit Knoechel, MD, PhD4, Jens G. Lohr, MD, PhD1 and Noopur Raje, MD7

1Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
2Department of Hematology, Oncology and Stem Cell Transplantation, University of Freiburg Medical Center, Freiburg, Baden Wurttemberg, Germany
3University of Alabama at Birmingham, Birmingham, AL
4Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
5Bristol Myers Squibb, Princeton, NJ
6Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
7Massachusetts General Hospital, Boston, MA

Ankit K. Dutta, PhD1,2,3*, Jean-Baptiste Alberge, PhD1,2,4*, Elizabeth D. Lightbody, PhD1,2,3, Cody J. Boehner, BS1,2*, Romanos Sklavenitis-Pistofidis, MD1,2,3, Amanda Cao2*, Tarek H. Mouhieddine, MD1,2,3, Anna Cowan, BA2*, Nang Kham Su, MSc1,2*, Andrew Dunford3*, Erica Horowitz, BA2*, Hadley Barr, BA1,2*, Jenna B. Beckwith, MPH2*, Laura Hevenor, BS2*, Jacqueline Perry, MPH1,2*, Ornkleaw Zepp5*, Thai Bui5*, Steven Gross, MA5*, Omar Nadeem, MD1,2, Chip Stewart, PhD3*, Daniel Auclair, PhD6,7, Gad Getz, PhD3,8* and Irene Ghobrial, MD1,2,3

1Department of Medicine, Harvard Medical School, Boston, MA
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
3Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA
4Broad Institute of MIT and Harvard, Cambridge, MA
5Menarini Silicon Biosystems, Huntingdon Valley, PA
6Multiple Myeloma Research Foundation, Norwalk, CT
7Hematology R&D, AstraZeneca, Waltham, MA
8Department of Pathology, Massachusetts General Hospital Cancer Center, Boston, MA

Debora Soncini, PhD1*, Pamela Becherini2*, Elisa Gelli, PhD3*, Claudia Martinuzzi2*, Fabio Guolo, MD1*, Antonino Neri, MD4, Antonia Cagnetta, MD1*, Roberto Massimo Lemoli, MD1 and Michele Cea1*

1Clinic of Hematology, Department of Internal Medicine (DiMI), IRCCS Ospedale Policlinico San Martino, Genova, Italy
2University of Genoa, Genoa, ITA
3DIMI, University of Genoa, Genova, Italy
4BMT Center - Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy

Jing Fu, PhD1, Shirong Li, PhD2, Huihui Ma, MD, PhD3*, Jun Yang, MS4*, Lewis M Brown, PhD5*, Gabriel M. Pagnotti, PhD6*, Stephen J. Weiss, MD, PhD7*, Markus Y. Mapara, MD, PhD3 and Suzanne Lentzsch, MD, PhD4

1Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, NY
2Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NJ
3Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY
4Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY
5Quantitative Proteomics Center, Columbia University, New York, NY
6Department of Endocrine, Neoplasia and Hormonal Disorders, University of Texas - MD Anderson Cancer Center, Houston, TX
7Department of Internal Medicine, University of Michigan, Life Sciences Institute, Ann Arbor, MI

Sridurga Mithraprabhu, PhD, MSc1,2*, John Reynolds, PhD3,4*, Rose Turner5*, Hang Quach6, Noemi Horvath, MB ChB FRACP FRCPA7, Ian H Kerridge, BA, BMed(Hons), MPhil(Cantab), FRACP, FRCPA8*, Flora Yuen, BBiomedSc3*, Tiffany Khong, BSc, PhD9, Brian G.M. Durie, MD10 and Andrew Spencer11

1Alfred Health - Monash University, Melbourne, Australia
2Myeloma Research Group, Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia
3The Alfred Hospital and Monash University, Melbourne, VIC, Australia
4Department of Haematology, The Alfred Hospital and Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia
5Alfred Hospital, Melbourne, Australia
6Clinical Haematology Service, St. Vincent’s Hospital, Melbourne, VIC, Australia
7Department of Haematology, Royal Adelaide Hospital, Adelaide, Australia
8Royal North Shore Hospital, Sydney, NSW, Australia
9Australian Center for Blood Diseases, Myeloma Research Group, Alfred Hospital, Monash University, Melbourne, VIC, Australia
10Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA
11Clinical Hematology, Alfred Health, Melbourne, Australia

Evan Flietner, BS1, Mei Yu, PhD2*, Adhithi Rajagopalan, PhD3, Yun Zhou, MS3*, Yubin Feng, PhD3*, Anthony Veltri, PhD2*, Terra L. Lasho, PhD4, Zhi Wen, PhD5*, Yuqian Sun3*, Robert Burns, PhD2*, Mrinal M. M. Patnaik, MD4, Natalie Callander, MD6, Fotis Asimakopoulos, PhD, MBBChir,7, Demin Wang, PhD2 and Jing Zhang, PhD3

1School of Medicine and Public Health, Cellular and Molecular Pathology Program, University of Wisconsin-Madison, Madison, WI
2Blood Research Institute, Versiti, Milwaukee, WI
3McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI
4Division of Hematology, Mayo Clinic, Rochester, MN
5Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield, WI
6Division of Hematology/Oncology, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI
7Department of Medicine, Division of Blood and Marrow Transplant, University of California San Diego & Moores Cancer Center, La Jolla, CA

Yanni Zhang, PhD1*, Zhen Sheng, PhD1*, Jie Xia1*, Chunyan Ye, PhD1*, Yan Liu, M.S.1*, Zhengyi Wang, PhD1*, John Hayslip, MD, MSCR2 and Andrew Zhu1*

1I-Mab Biopharma, Shanghai, China
2I-Mab Biopharma, Gaithersburg, MD

Takahiro Kamiya, MD1,2*, Motohiko Oshima, PhD1*, Shuhei Koide, PhD1*, Yaeko Nakajima-Takagi, PhD1*, Kazumasa Aoyama, PhD1*, Naoki Itokawa, MD, PhD1*, Masayuki Yamashita, MD, PhD1*, Noriko Doki, MD, PhD3*, Keisuke Kataoka, MD, PhD2,4 and Atsushi Iwama, MD, PhD1

1Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
2Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
3Hematology Division, Komagome Hospital, Tokyo, Japan
4Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan

Yoon Seok Choi, MD, PhD1,2, Yuri Lee, MS1,2*, Jun Soung Park, MD1*, Minsuk Kwon, MD, PhD1*, Seong Hyun Jeong, MD1*, Jeong Seok Lee, MD, PhD3*, Eui-Cheol Shin, MD, PhD3* and Joon Seong Park1*

1Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea, Republic of (South)
2Department of Biomedical Science, Ajou University Graduate School, Suwon, Korea, Republic of (South)
3Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea, Republic of (South)

Anna Maria Corsale1*, Mojtaba Shekarkar Azgomi, PhD1*, Federica Plano1*, Marta Di Simone1*, Cristina Perez2*, Carmela Picone3*, Emilia Gigliotta1*, Candida Vullo1*, Giulia Camarda1*, Cristina Rotolo1*, Maria Speciale1*, Marco Santoro, MD, PhD1*, Nadia Caccamo3*, Francesco Dieli3*, Bruno Paiva2*, Serena Meraviglia3*, Sergio Siragusa, MD1 and Cirino Botta, MD, PhD1

1Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, Italy
2Centro de Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra Hematology Unit, Clinica Universitad de Navarra, Centro de Investigacion Biomedica en Red, Cancer Hematology Unit, Pamplona, Spain
3Department of Biomedicine, Neurosciences and Advanced Diagnosis, University of Palermo, Palermo, Italy

Scott R. Goldsmith, MD1,2, Reyka G. Jayasinghe, PhD3*, Jonathan Adam Scolnick, PhD4*, Jaren Sia5*, Mark A Fiala, PhD6*, Michael J Slade, MD, MS7, Tianjiao Wang8, Li Ding, PhD9* and Ravi Vij, MD10

1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
2Division of Myeloma, Department of Hematology and HCT, City of Hope Comprehensive Cancer Center, Duarte, CA
3Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
4Singleron Biothechnologies, Singapore, AL, Singapore
5Singleron Biotechnologies, Singapore, Singapore
6Department of Medicine, Division of Hematology & Oncology, Washington University School of Medicine, St. Louis, MO
7Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
8Medicine, Washington University School of Medicine, Saint Louis, MO
9Department of Medicine, Washington University School of Medicine, Saint Louis, MO
10Division of Oncology, Washington University School of Medicine, Saint Louis, MO

Young Eun Lee, MS1,2*, Ju Heon Park, MD1*, Ha Jin Lim, MD1*, Hye Ran Kim, PhD3*, Jong Hee Shin, MD, PhD1* and Myung-Geun Shin, MD, PhD1,2,4

1Department of Laboratory Medicine, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of (South)
2BioMedical Sciences Graduate Program (BMSGP), Chonnam National Univerisity and Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of (South)
3College of Korean Medicine, Dongshin University, Naju, Korea, Republic of (South)
4KBlueBio Inc., Hwasun, Korea, Republic of (South)

Kentaro Mizuhara1*, Yuji Shimura, MD, PhD1*, Taku Tsukamoto, MD, PhD1*, Akinori Kanai, PhD2,3*, Saeko Kuwahara-Ota, MD, PhD1,4*, Junko Yamaguchi, MD, PhD1,5*, Ayako Muramatsu, MD1*, Haruya Okamoto, MD1*, Yoko Katsuragawa-Taminishi, MD1*, Yuka Kawaji-Kanayama, MD1*, Reiko Isa, MD1*, Shinsuke Mizutani, MD, PhD1*, Toshiya Inaba2* and Junya Kuroda, MD, PhD1

1Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan
2Department of Molecular Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
3Laboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, the University of Tokyo, Chiba, Japan
4Department of Hematology, Japan Community Health Care Organization, Kyoto Kuramaguchi Medical Center, Kyoto, Japan
5Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan

Mateo Mejia Saldarriaga, MD1, Aubrie Sowa1,2*, David S Jayabalan, MSc3*, Cara A. Rosenbaum, MD1*, Roger Pearse, MD, PhD1, Jorge Monge, MD4, Ruben Niesvizky, MD1 and Mark Bustoros, MD1

1Division of Hematology & Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
2University College Dublin Medical School, Dublin, Ireland
3Department of Pathology & Laboratory Medicine, Weill Cornell Medical College, New York, NY
4Hematology & Medical Oncology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY

Guangfeng Wang, PhD1*, Eric Liang, PhD2*, Ping Min, MS1*, Yangfeng Ge, BS1*, Bingxing Wu, BS3*, Huidan Yu, BS3*, Dajun Yang2,4* and Yifan Zhai2

1Ascentage Pharma Co., Ltd., Shanghai, China
2Ascentage Pharma Group Inc., Rockville, MD
3Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China
4Department of Experimental Research, State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

Yao Yao1,2*, Jessica Fong Ng3*, Woojun D Park4*, Mehmet K. Samur, PhD5, Eugenio Morelli, MD6, Nicholas P Kwiatkowski, PhD7,8*, Jessica Encinas Mayoral9*, Zuzana Chyra10*, Yan Xu, MD11*, Behnam Nabet, PhD5*, Marta Chesi, PhD12, Nathaniel Gray13*, Richard A. Young, PhD14*, Kenneth C. Anderson, MD5, Charles Y Lin, PhD15*, Nikhil C Munshi, MD, PhD6 and Mariateresa Fulciniti, PhD5

1Dana Farber Cancer Institute, Boston, MA
2Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China
3Dana farber cancer institute, Boston, MA
4Baylor college of medicine, Huston, TX
5Dana-Farber Cancer Institute, Boston, MA
6Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
7Biological Chemistry and Molecular Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
8Broad Institute of MIT and Harvard, Cambridge, MA
9Hospital Doce de Octubre, Madrid, Spain
10Department of Hematooncology, University Hospital of Ostrava; Masaryk University, Ostrava, Czech Republic
11Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
12Mayo Clinic, Scottsdale, AZ
13Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford Medicine, Stanford, CA
14Whitehead Institute For Biomedical Research/ MIT, Cambridge, MA
15Dan L. Duncan Cancer Center, Department of Molecular and Human Genetics, Baylor College of Medicine, HOUSTON, TX

Melissa R Junttila, PhD1*, Arghya Ray, PhD2, Robert Warne1*, Xi R Chen1*, Ting Du2*, Fang Lui1*, Subhash Katewa, PhD1*, Brian Blank, PhD1*, Jared Moore, PhD1*, Chudi Ndubaku, PhD1*, Christophe Colas, PhD1*, Pratik S Multani, MD1*, Omar Nadeem, MD2*, Dharminder Chauhan, PhD2*, Kenneth C. Anderson, MD3 and Lori Friedman, PhD1*

1ORIC Pharmaceuticals, South San Francisco, CA
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
3The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Mara John1*, Moutaz Helal2*, Lars Grundheber2*, Greta Mattavelli2*, Nazia Afrin2*, Xiang Zhou3*, Benedict Engel2*, Werner Schmitz4*, Emilia Stanojkovska5*, Cornelia Vogt, MSc6*, Silvia Nerreter6*, Eva Teufel, MSc6*, Julia Mersi, MD6*, Hermann Einsele, MD7, K. Martin Kortuem8*, Angela Riedel9* and Leo Rasche, MD6*

1Mildred Scheel Early Career Center (MSNZ), University Hospital Wuerzburg, Wuerzburg, DEU
2Mildred Scheel Early Career Center (MSNZ), University Hospital Würzburg, Würzburg, Germany
3Department of Internal Medicine II, University Hospital Wuerzburg, WüRzburg, Germany
4Biozentrum, University Würzburg, Würzburg, Germany
5Mildred Scheel Early Career Center (MSNZ), University Hospital Würzburg, Würzburg, DEU
6Department of Internal Medicine II, University Hospital Wuerzburg, Wuerzburg, Germany
7Universitaetsklinikum Wuerzburg, Med. Klinik und Poliklinik II, Wuerzburg, Germany
8Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
9University Hospital Wuerzburg, Wuerzburg, DEU

James P Roy1,2*, Georgina S.F. Anderson1,2*, Ieuan Walker, MBBS, MSc, BSc, MRCP1,3* and Michael A Chapman, PhD, MRCP, FRCPath1,2,3

1MRC Toxicology Unit, University of Cambridge, Cambridge, United Kingdom
2Department of Haematology, University of Cambridge, Cambridge, United Kingdom
3Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom

Chengcheng Liao, PhD, MD1*, Srikanth Talluri, PhD1*, Shidai Mu, MD, PHD1*, Subodh Kumar, PhD1*, Lakshmi B. Potluri, MD1*, Jialan Shi, MD, PhD1, Leutz Buon1*, Masood A. Shammas, PhD1* and Nikhil C Munshi, MD, PhD2,3

1Dana-Farber Cancer Institute, Boston, MA
2Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
3VA Boston Healthcare System, Boston

Remi Tilmont, MD*, Ranjan Maity, PhD*, Noemie Leblay, PhD*, Holly Lee, MD, Elie Barakat, MSc*, Paola Neri, MD, PhD and Nizar J. Bahlis, MD

Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada

Gabriel Alvares Borges, PhD, MSc, DDS1*, Angelo Jose Guilatco, BS1,2*, Christine M. Hachfeld1*, Ming Ruan3*, Sonya Royzenblat4*, Ming Xu, PhD, BS5*, Claire M. Edwards, PhD6*, Marta Diaz-delCastillo, PhD7*, Thomas L. Andersen, PhD7*, Taxiarchis Kourelis, MD1, Tamar Tchkonia, PhD3*, James L. Kirkland, MD/PhD3*, Matthew T. Drake, MD, PhD1,3,8 and Megan Weivoda, PhD1

1Division of Hematology, Mayo Clinic, Rochester, MN
2Cancer Biology Graduate Program, University of Michigan, Ann Arbor, MI
3Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN
4Cellular and Molecular Biology Program, University of Michigan, Ann Arbor, MI
5Center on Aging and the Department of Genetics and Genome Sciences, University of Connecticut, Farmington, CT
6Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
7Department of Forensic Medicine, Aarhus University Hospital, Aarhus, Denmark
8Division of Endocrinology, Mayo Clinic, Rochester, MN

Hailin Chen, MD1*, Tengteng Yu, MD2*, Liang Lin, PhD1*, Lijie Xing, MD3*, Shih-Feng Cho, MD, PhD4*, Kenneth Wen1*, Kimberly Aardalen5*, Mike Daley6*, Haihui Lu, PhD7, Adwait Oka7*, Joni Lam6*, Nikhil C Munshi, MD, PhD8, Kenneth C. Anderson, MD9 and Yu-Tzu Tai, PhD10

1Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA
2the Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
3Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
4Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
5Novartis Institutes For Biomedical Research, Cambridge, MA
6Novartis Institutes for Biomedical Research, Cambridge
7Novartis Institutes for Biomedical Research, Cambridge, MA
8Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
9LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
10Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

Nathan Becker, MS1*, Enze Liu, PhD1*, Parvathi Sudha, MS1*, Aneta Mikulasova2*, Travis S Johnson, PhD3, Attaya Suvannasankha, MD1, Mohammad Issam Abu Zaid, MBBS1, Rafat Abonour, MD1 and Brian A. Walker, PhD1

1Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University, Indianapolis, IN
2Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
3Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN

Li Du, PhD1,2*, Wei Liu, PhD3,4*, Enrico Caserta, PhD5,6*, Flavia Pichiorri, PhD5,7 and Steve T Rosen, MD8,9

1Toni Stephenson Lymphoma Center, Beckman Research Institute City of Hope, Duarte, CA
2Judy and Bernard Briskin Center for Multiple Myeloma Research, Beckman Research Institute City of Hope, Duarte, CA
3Xiangya Hospital Central South University, Changsha, China
4Beckman Research Institute City of Hope, Duarte, CA
5Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
6Department of Hematologic Malignancies Translational Science, Beckman Research Institute, City of Hope, Duarte, CA
7Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA
8City of Hope National Medical Center, Duarte, CA
9City of Hope Comprehensive Cancer Center, Duarte, CA

Ko Abe1*, Sho Ikeda, MD1*, Miho Nara, MD1*, Akihiro Kitadate, MD, PhD2, Hiroyuki Tagawa, MD, PhD1 and Naoto Takahashi, MD, PhD1

1Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan
2Department of Hematology, Nephrology, and Rheumatology, Akita University, Akita, Japan

Lixin Gong1*, Hao Sun, PhD2*, Junqiang Lv3*, Lugui Qiu4 and Mu Hao, PhD1*

1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
2State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, Tianjin,China, China
3Tianjin Medical UniversityKey Laboratory of Immune Microenvironment and Diseases (Ministry of Education), Department of Immunology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
4State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Moritz Binder, MD, MPH1, Amelia Mazzone, PhD2*, Jenna A. Fernandez, PhD1*, Wazim Mohammed Ismail, PhD2*, S. Vincent Rajkumar, MD1*, Alexandre Gaspar Maia, PhD2* and Shaji K Kumar, MD1

1Division of Hematology, Mayo Clinic, Rochester, MN
2Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

Sara ovejero-Merino, PhD1*, Julie Devin, PharmD2*, Tatiana Cañeque3*, Laura Alibert4*, Guilhem Requirand5*, Nicolas Robert5*, Alizée Steer, PhD6,7*, Amelie Machura7*, Christophe Hirtz8*, Angélique Bruyer6,7*, Laure Vincent, MD9*, Guillaume Cartron, MD, PhD10*, Charles Herbaux11,12,13,14, Raphael Rodriguez3*, Caroline Bret, PhD, PharmD6,15,16* and Jerome Moreaux, PhD5,6,17,18

1Institute of Human Genetics, Montpellier, FRA
2CHU Montpellier, Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, Montpellier, France
3Institut Curie, Paris, France
4Institute of human genetics, Montpellier, France
5Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, CHU Montpellier, Montpellier, France
6Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France
7Diag2Tec, Montpellier, France
8CHU Montpellier, Laboratory of Biochemistry – Clinical Proteomic, Montpellier, France
9Department of Hematology, Montpellier University Hospital, Montpellier, France
10Département d'Hématologie clinique, CHU de Montpellier, Montpellier, France
11Hematology Department, Montpellier University Hospital, Montpellier, France, Montpellier, France
12University of Montpellier, Paris, France
13University of Montpellier, Montpellier, France
14CHU de Montpellier, Montpellier, France
15Department of Biological Hematology, CHU Montpellier, Montpellier, France
16University of Montpellier, UFR Medecine, Montpellier, France
17UFR Médecine, Université Montpellier, Montpellier, France
18Institut Universitaire de France, Paris, France

Sabrin Tahri, MD1,2*, Madelon M.E. de Jong, MD3*, Cathelijne Fokkema, MD3*, Natalie Papazian, BSc3*, Zoltan Kellermayer, MD, PhD4*, Michael Vermeulen, BSc3*, Mark van Duin, PhD3*, Pieter van de Woestijne, MD PhD5*, Kazem Nasserinejad, PhD6*, Elona Saraci7*, Mattia D'Agostino, MD7*, Francesca Gay, MD, PhD7, Vincent H.J. van der Velden, PhD8*, Niels WCJ Van De Donk, MD9, Annemiek Broijl, MD, PhD10*, Pieter Sonneveld, MD11, Sonja Zweegman, MD, PhD12 and Tom Cupedo, PhD3*

1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, MA, Netherlands
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
3Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
4Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, NLD
5Department of Thoracic Surgery, Erasmus MC, Rotterdam, Netherlands
6Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands
7Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
8Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
9Department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands
10Erasmus MC Cancer Institute, Rotterdam, Netherlands
11Erasmus MC Cancer Institute, Department of Hematology, Rotterdam, Netherlands
12Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, Netherlands

Alexandre Tang, PhD1*, Laurent Gauthier, PhD2*, Jochen Beninga3*, Benjamin Rossi2*, Nicolas Gourdin2*, Audrey Blanchard-Alvarez2*, Céline Amara4*, Jacqueline Courta5*, Alexandra Basset6*, Dorothee Bourges1*, Alexandre Desjonqueres, MD, MSc1*, Emmanuelle Menoret, PhD7*, Catherine Pellat-Deceunynck, PhD7, Philippe Moreau, MD7*, Yannis Morel, PhD2*, Marielle Chiron1*, Angela Virone-Oddos, PhD1* and Eric Vivier, PhD2*

1Oncology Research, Sanofi, Vitry-sur-Seine, France
2Innate Pharma, Marseille, France
3Large Molecule Research, Sanofi, Frankfurt am Main, Germany
4Drug Metabolism and Pharmacokinetics, Sanofi, Chilly Mazarin, France
5TMED Biomarkers and Clinical Bioanalysis, Sanofi, Chilly Mazarin, France
6Preclinical Safety, Sanofi, Chilly Mazarin, France
7CRCINA, INSERM, CNRS, Angers University and Nantes University, Nantes, France

Alexandra M. Poos, PhD1,2*, Nina Prokoph, PhD1,2*, Moritz J. Przybilla, MSc3,4,5*, Jan-Philipp Mallm, PhD6*, Simon Steiger7*, Isabelle Lander, MSc7*, Lukas John, MD1,2*, Stephan M Tirier, PhD7*, Katharina Bauer6*, Anja Baumann1,2*, Umair Munawar, PhD8*, Leo Rasche, MD8,9*, Martin Kortuem8*, Nicola Giesen, MD1,2*, Stefanie Huhn, PhD2*, Carsten Mueller-Tidow, MD2,10, Hartmut Goldschmidt, MD2,10, Oliver Stegle, PhD3,5*, Marc S Raab, MD1,2*, Karsten Rippe, PhD7* and Niels Weinhold, PhD1,2*

1Clinical Cooperation Unit (CCU) Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
2Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
3Division of Computational Genomics and Systems Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
4Wellcome Sanger Institute, Cambridge, United Kingdom
5Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
6Single Cell Open Lab, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany
7Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany
8Department of Internal Medicine II, University Hospital Wuerzburg, Wuerzburg, Germany
9Mildred Scheel Early Career Center (MSNZ), University Hospital of Wuerzburg, Wuerzburg, Germany
10National Center for Tumor Diseases (NCT), Heidelberg, Germany

Sivasubramanian Baskar, PhD1*, Haiyong Peng, Ph.D.2*, Christoph Rader, Ph.D.2* and Adrian Wiestner, MD3

1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
2Department of Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida, Jupiter, FL
3Hematology Branch, National Heart, Lung, and Blood Institute, NIH, NHLBI, Bethesda, MD

Anish K Simhal, PhD1, Kylee H Maclachlan, MBBCh, PhD2, Rena Elkin, PhD1*, Jiening Zhu3*, Saad Usmani, MD2, Jonathan J Keats, PhD4, Larry Norton, MD5*, Joseph O. Deasy, PhD1*, Jung Hun Oh, PhD1* and Allen Tannenbaum, PhD6*

1Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
2Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
3Department of Applied Mathematics & Statistics, Stony Brook University, Stony Brook, NY
4Translational Genomics Research Institute, Phoenix, AZ
5Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
6Departments of Computer Science and Applied Mathematics & Statistics, Stony Brook University, Stony Brook, NY

*signifies non-member of ASH